Roche Bets Up to $1.16 Billion on Rona’s ALK7 Drug
Roche licensed Rona Therapeutics’ investigational RNAi candidate targeting ALK7 for up to $1.16 billion. The deal includes upfront and near-term payments, plus tiered royalties on global net sales.
RNA interference 1 article
RNA interference is a post-transcriptional gene-silencing mechanism in which small RNA guides direct Argonaute-containing RISC complexes to complementary RNA targets. siRNAs can trigger sequence-specific mRNA cleavage, while endogenous microRNA pathways use related machinery to regulate transcript stability or translation. The entity denotes the biological mechanism itself, distinct from a particular siRNA molecule, delivery system or RNAi drug designed against one therapeutic target.